Ann: Appendix 4E and Annual Report, page-76

Every other drug on clinical trial wants to get that status the least, this was 1980 dude nobody knew what cancer was properly, even AIDS was treated with chemotherapy, Bisantrene has been historically approved and used as a salvage therapy for specific cases, particularly in treating refractory or relapsed AML. However, its broad approval for use was limited,

1. its comparable with Anthracyclines, Anthracyclines are a class of chemotherapy drugs known for their efficacy but are often limited by their potential to cause heart damage (cardiotoxicity)

2. Bisantrene is associated with myelosuppression, which is the suppression of bone marrow activity, leading to decreased production of blood cells (white blood cells, red blood cells, and platelets). This can result in increased risk of infections, anemia, and bleeding complications

3. Apart from myelosuppression, other hematologic toxicities, such as neutropenia (a decrease in neutrophils, a type of white blood cell), can occur. This condition increases the risk of infections, particularly in patients undergoing chemotherapy for hematologic malignancies like AML.

4. Additional side effects reported include skin reactions at the injection site (e.g., phlebitis), alopecia (hair loss), and mucositis (inflammation of the mucous membranes in the mouth and digestive tract). These are typical side effects associated with many chemotherapy agents due to their impact on rapidly dividing cells.

When you have AML the side effects are the ones which kill the patient early, not the cancer, patients need to get blood everytime the blood cells decrease and they get secondary infection which cannot be cured due to immune system supression